

Cite this: DOI: 10.1039/c0xx00000x

www.rsc.org/xxxxxx

ARTICLE TYPE

Supplementary information *In vitro* anticancer activity and SAR of triazolyl aminoacyl(peptidyl) penicillins

Patricia G. Cornier,^a Carina M. L. Delpiccolo,^a Florencia^aMascali,^a Dora B. Boggián,^a Ernesto G. Mata,^{a,*}
₅ Mariano Cárdenas,^b Viviana Blank,^b Leonor P. Roguin^{b,*}

Received (in XXX, XXX) Xth XXXXXXXXXX 20XX, Accepted Xth XXXXXXXXXX 20XX

DOI: 10.1039/b000000x

Experimental

1. Chemistry

Solvents were analytical grade or were purified by standard procedures prior to use. Infrared spectra (IR) were recorded on a Shimadzu Prestige 21 spectrophotometer and only partial spectral data are listed. The ¹H and ¹³C NMR spectra were acquired in the specified solvent, in a Bruker Avance spectrometer (300 and 75 MHz for ¹H and ¹³C, respectively), with tetramethylsilane (TMS) as internal standard. The chemical shifts (δ) are reported in ppm downfield from TMS and coupling constants (J) are expressed in hertz. The high resolution mass spectra were obtained with a Bruker MicroTOF-Q II instrument (Bruker Daltonics, Billerica, MA). Detection of the ions was performed in electrospray ionization, positive ion mode. Flash column chromatography was performed using Merck silica gel 60 (230–400 mesh). Elution was carried out with hexane-EtOAc mixtures, under positive pressure and employing gradient of solvent polarity techniques.

1.1. (2S)-2-(1-((2S)-6,6-Dibromo-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptan-2-yl)methyl)-1H-1,2,3-triazole-4-carboxamido)-3-phenylpropanoic acid (6b)

¹H NMR (CDCl₃, 300 MHz) δ 1.53 (s, 3H, CH₃), 1.56 (s, 3H, CH₃), 3.26 (m, 2H, CH₂), 4.35 (m, 1H, CH₂), 4.47 (m, 1H, CH), 4.63 (1m, 1H, CH), 5.00 (m, 1H, CH), 5.63 (s, 1H, CH), 7.16–7.29 (m, 5H, ArH), 7.44 (d, J =7.6 Hz, 1H, NH), 8.33 (s, 1H, CH). ¹³C NMR (CDCl₃, 75 MHz) δ 24.4 (CH₃), 33.2 (CH₃), 37.4 (CH₂), 48.3 (CH₂), 53.4 (CH), 58.6 (C), 63.7 (C), 67.8 (CH), 78.3 (CH), 127.2 (CH), 128.7 (CH), 129.3 (CH), 135.8 (C), 142.6 (C), 160.1 (CO), 165.7 (CO), 173.9 (CO). IR: (film) 1789 cm⁻¹ (β -lactam), 1740 cm⁻¹ (CO₂H), 1670 cm⁻¹ (CO amide). HRMS-ESI (m/z): calcd for C₂₀H₂₁Br₂N₅NaO₄S [M+Na]⁺: 607.9579; found 607.9573.

1.2. (2S)-2-(1-((2S)-6,6-Dibromo-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptan-2-yl)methyl)-1H-1,2,3-triazole-4-carboxamido)-3-methylbutanoic acid (6c)

¹H NMR (CDCl₃, 300 MHz) δ 1.05 (m, 3H, CH₃), 1.06 (m, 3H, CH₃), 1.57 (s, 3H, CH₃), 1.58 (s, 3H, CH₃), 2.34 (m, 1H, CH), 4.37–4.50 (m, 2H, CH and CH₂), 4.66–4.71 (m, 2H, CH and CH₂), 5.68 (s, 1H, CH), 7.67 (d, 1H, NH, J =8.4 Hz) 8.42 (s, 1H, CH).

¹³C NMR (CDCl₃, 75 MHz) δ 17.9 (CH₃), 19.2 (CH₃), 24.5 (CH₃), 30.9 (CH), 33.3 (CH₃), 48.3 (CH₂), 57.4 (C), 58.6 (CH), 63.7 (C), 67.9 (CH), 78.3 (CH), 126.8 (CH), 142.8(C), 159.9 (CO), 160.3 (CO), 165.7 (CO). IR: (film) 1789 cm⁻¹ (β -lactam), 1730 cm⁻¹ (CO₂H), 1665 cm⁻¹ (CO amide). HRMS-ESI (m/z): calcd for C₁₆H₂₁Br₂N₅NaO₄S [M+Na]⁺: 559.9579; found 559.95732.

1.3. Methyl 2-(1-((2S)-6,6-dibromo-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptan-2-yl)methyl)-1H-1,2,3-triazole-4-carboxamido)acetate (7a)

¹H NMR (CDCl₃, 300 MHz) δ 1.57 (s, 3H, CH₃), 1.59 (s, 3H, CH₃), 3.79 (s, 3H, CH₃), 4.25 (d, J =5.64 Hz, 2H, CH₂), 4.37 (m, 1H, CH₂), 4.42 (m, 1H, CH), 4.70 (dd, J_1 =12.6 Hz, J_2 =3 Hz, 1H, CH₂), 5.64 (s, 1H, CH), 7.63 (t, J =5.64 Hz, 1H, NH), 8.23 (s, 1H, CH). ¹³C NMR (CDCl₃, 75 MHz) δ 24.5 (CH₃), 33.2 (CH₃), 40.9 (CH₂), 48.3 (CH₂), 52.5 (CH₃), 58.5(C), 63.6 (C), 67.9 (CH), 78.4 (CH), 126.1 (CH), 143.1 (C), 159.9 (CO), 165.6 (CO), 169.7 (CO). IR: (film) 1789 cm⁻¹ (β -lactam), 1747 cm⁻¹ (CO ester), 1672 cm⁻¹ (CO amide). HRMS-ESI (m/z): calcd. for C₁₄H₁₇Br₂N₅O₄S [M+Na]⁺: 531.9265; found 531.9260.

1.4. (2S)-Methyl 2-(1-((2S)-6,6-dibromo-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptan-2-yl)methyl)-1H-1,2,3-triazole-4-carboxamido)-3-methylbutanoate (7c).

¹H NMR (CDCl₃, 300 MHz) δ 1.00 (d, J =3.4 Hz, 3H, CH₃), 1.02 (d, J =3.4 Hz, 3H, CH₃), 1.57 (s, 3H, CH₃), 1.59 (s, 3H, CH₃), 2.28 (m, 1H, CH), 3.77 (s, 3H, OCH₃), 4.31 (m, 1H, CH₂), 4.41 (m, 1H, CH), 4.70 (m, 1H, CH₂), 4.72 (m, 1H, CH), 5.68 (s, 1H, CH), 7.57 (d, J =9Hz, 1H, NH) 8.32 (s, 1H, CH). ¹³C NMR (CDCl₃, 300 MHz) δ 17.9 (CH₃), 19.1(CH₃), 24.5 (CH₃), 31.4 (CH), 33.3 (CH₃), 48.3 (CH₂), 52.3 (OCH₃), 57.1 (CH₃), 58.6(C), 63.5 (C), 67.9 (CH), 78.4 (CH), 126.4 (CH), 143.2 (C), 159.7 (CO), 165.6 (CO), 171.7 (CO). IR: (film) 1789 cm⁻¹ (β -lactam), 1745 cm⁻¹ (CO ester), 1666 cm⁻¹ (CO amide). HRMS-ESI (m/z): calcd for C₁₅H₁₉Br₂N₅NaO₄S [M+Na]⁺: 573.9735; found 573.9729.

1.5. (2S)-Methyl 2-(1-((2S)-6,6-dibromo-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptan-2-yl)methyl)-1H-1,2,3-triazole-4-carboxamido)-3-phenylpropanoate (7b).

¹H NMR (CDCl₃, 300 MHz) δ 1.57 (s, 3H, CH₃), 1.59 (s, 3H,

CH₃), 3.22 (m, 2H, CH₂), 3.73 (s, 3H, OCH₃), 4.38 (m, 1H, CH) 4.68 (dd, $J_1=12.6$ Hz, $J_2=2.7$ Hz, 2H, CH₂), 5.05 (m, 1H, CH), 5.64 (s, 1H, CH), 7.16-7.31 (m, 5H, ArH), 7.54 (d, $J=8.46$ Hz, 1H, NH), 8.19 (s, 1H, CH). ¹³C NMR (CDCl₃, 75 MHz) δ 24.5 (CH₃), 33.2 (CH₃), 38.2 (CH₂), 48.3 (CH₂), 52.4 (CH₃), 53.2 (CH), 58.5 (C), 63.6 (C), 67.9 (CH), 78.4 (CH), 126.1 (CH), 127.2 (CH), 128.6 (CH), 129.2 (CH), 135.7 (C), 143.0 (C), 159.34 (CO), 165.5 (CO), 171.3 (CO). IR: (film) 1789 cm⁻¹ (β-lactam), 1745 cm⁻¹ (CO ester), 1672 cm⁻¹ (CO amide). HRMS-ESI (*m/z*): calcd for C₂₁H₂₃Br₂N₅O₄S [M+H]⁺: 599.9915; found 599.9910.

1.6. (2S)-Methyl 2-(2-(1-((2S)-6,6-dibromo-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptan-2-yl)methyl)-1H-1,2,3-triazole-4-carboxamido)acetamido)-3-phenylpropanoate (7d)

¹H NMR (CDCl₃, 300 MHz) δ 1.57 (s, 3H, CH₃), 1.60 (s, 3H, CH₃), 3.11 (ddd, $J_1=21$ Hz, $J_2=14$ Hz, $J_3=6$ Hz, 2H, CH₂), 3.70 (s, 3H, OCH₃), 4.11 (d, $J=5.7$ Hz, 2H, CH₂), 4.36 (m, 1H, CH₂), 4.46 (m, 1H, CH), 4.69 (dd, $J_1=13$ Hz, $J_2=3.8$ Hz, 2H, CH₂), 4.89 (m, 1H, CH), 5.65 (s, 1H, CH), 6.70 (d, $J=7.6$ Hz, 1H, NH), 7.07-7.22 (m, 5H, ArH), 7.79 (t, $J=5.7$ Hz, 1H, NH), 8.25 (s, 1H, CH). ¹³C NMR (CDCl₃, 75 MHz) δ 24.5 (CH₃), 33.2 (CH₃), 37.8 (CH₂), 42.9 (CH₂), 48.4 (CH₂), 52.4 (CH₃), 53.2 (CH), 58.5 (C), 63.6 (C), 67.9 (CH), 78.4 (CH), 126.2 (CH), 127.1 (CH), 128.6 (CH), 129.2 (CH), 135.7 (C), 142.9 (C), 160.2 (CO), 165.6 (CO), 168.14 (CO), 171.8 (CO). IR: (film) 1789 cm⁻¹ (β-lactam), 1745 cm⁻¹ (CO ester), 1690 cm⁻¹ (CO amide). HRMS-ESI (*m/z*): calcd for C₂₃H₂₆Br₂N₆NaO₅S [M+Na]⁺: 678.9944; found 678.9943.

1.7. (2S)-Methyl 2-((2S)-2-(1-((2S)-6,6-dibromo-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptan-2-yl)methyl)-1H-1,2,3-triazole-4-carboxamido)-4-methylpentanamido)-3-(4-hydroxyphenyl)propanoate (7e).

¹H NMR (CDCl₃, 300 MHz) δ 0.90 (d, $J=6.2$ Hz, 3H, CH₃), 0.93 (d, $J=6.2$ Hz, 3H, CH₃), 1.59 (s, 3H, CH₃), 1.59-1.76 (m, 2H, CH₂), 1.61 (s, 3H, CH₃), 2.97 (dd, $J_1=14$ Hz, $J_2=6.54$ Hz, 1H, CH₂), 3.10 (dd, $J_1=14$ Hz, $J_2=5.4$ Hz, 1H, CH₂), 3.76 (s, 3H, OCH₃), 4.33 (dd, $J_1=14$ Hz, $J_2=10.9$ Hz, 1H, CH₂), 4.51 (dd, $J_1=11$ Hz, $J_2=3.4$ Hz, 1H, CH), 4.59-4.67 (m, 1H, CH), 4.74-4.86 (m, 2H, CH and CH₂), 5.71 (s, 1H, CH), 6.46 (d, $J=8.4$ Hz, 2H, ArH), 6.76 (d, $J=8$ Hz, 1H, NH), 6.84 (d, $J=8.4$ Hz, 2H, ArH), 7.37 (d, $J=8.4$ Hz, 1H, NH), 8.22 (s, 1H, CH). ¹³C NMR (CDCl₃, 75 MHz) δ 21.9 (CH₃), 22.9 (CH₃), 24.7 (CH₃), 33.2 (CH₃), 36.5 (CH₂), 39.9 (CH₂), 48.4 (CH₂), 51.1 (CH), 52.5 (CH), 53.0 (CH) 58.0 (C), 63.6 (C), 68.2 (CH), 78.5 (CH), 115.3 (CH), 126.9 (CH), 130.3 (CH), 142.8 (C), 155.0 (C), 159.8 (CO), 166.7 (CO), 170.8 (CO), 171.9 (CO). IR: (film) 1789 cm⁻¹ (β-lactam), 1747 cm⁻¹ (CO ester), 1670 cm⁻¹ (CO amide). HRMS-ESI (*m/z*): calcd for C₂₇H₃₄Br₂N₆NaO₆S [M+Na]⁺: 751.05195; found: 751.05135.

1.8. (2S)-Methyl 2-((2S)-2-(1-((2S)-6,6-dibromo-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptan-2-yl)methyl)-1H-1,2,3-triazole-4-carboxamido)-4-methylpentanamido)-3-phenylpropanoate (7f).

¹H NMR (CDCl₃, 300 MHz) δ 0.91 (d, $J=5.6$ Hz, 3H, CH₃), 0.92 (d, $J=5.6$ Hz, 3H, CH₃), 1.57 (s, 3H, CH₃), 1.60 (s, 3H,

CH₃), 1.59-1.76 (m, 3H, CH and CH₂), 3.04 (dd, $J_1=13.7$ Hz, $J_2=6.3$ Hz, 1H, CH₂), 3.14 (dd, $J_1=13.7$ Hz, $J_2=5.7$ Hz, 1H, CH₂), 3.69 (s, 3H, OCH₃), 4.37 (dd, $J_1=13.3$ Hz, $J_2=10$ Hz, 1H, CH₂), 4.49 (dd, $J_1=10$ Hz, $J_2=3.9$, 1H, CH), 4.60 (m, 1H, CH), 4.70 (dd, $J_1=13.3$ Hz, $J_2=3.9$, 1H, CH₂), 4.87 (m, 1H, CH), 5.66 (s, 1H, CH), 6.75 (d, $J=8$ Hz, 1H, NH), 7.04-7.15 (m, 5H, ArH), 7.38 (d, $J=8.2$ Hz, 1H, NH), 8.26 (s, 1H, CH). ¹³C NMR (CDCl₃, 75 MHz) δ 21.9 (CH₃), 22.9 (CH₃), 24.5 (CH), 24.6 (CH₃), 33.3 (CH₃), 37.9 (CH₂), 40.7 (CH₂), 48.4 (CH₂), 51.3 (CH), 52.3 (CH), 53.2 (CH) 58.5 (C), 63.7 (C), 67.9 (CH), 78.4 (CH), 126.2 (CH), 127.0 (CH), 128.5 (CH), 129.2 (CH), 135.6 (C), 143.0 (C), 159.7 (CO), 165.6 (CO), 171.0 (CO), 171.8 (CO). IR: (film) 1797 cm⁻¹ (β-lactam), 1744 cm⁻¹ (CO ester), 1670 cm⁻¹ (CO amide). HRMS-ESI (*m/z*): calcd for C₂₇H₃₄Br₂N₆NaO₅S [M+Na]⁺: 735.05704; found: 735.05518.

1.9. (2S)-Methyl 2-((2S,3S)-2-(1-((2S)-6,6-dibromo-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptan-2-yl)methyl)-1H-1,2,3-triazole-4-carboxamido)-3-methylpentanamido)-3-phenylpropanoate (7h).

¹H NMR (CDCl₃, 300 MHz) δ 0.86 (t, $J=7.2$ Hz, 3H, CH₃), 0.93 (d, $J=6.6$ Hz, 3H, CH₃), 1.13 (m, 1H, CH₂), 1.48 (m, 1H, CH₂), 1.55 (s, 3H, CH₃), 1.57 (s, 3H, CH₃), 1.96 (m, 1H, CH), 3.05 (dd, $J_1=13.8$ Hz, $J_2=6.3$ Hz, 1H, CH₂), 3.13 (dd, $J_1=13.8$ Hz, $J_2=5.9$, 1H, CH₂), 3.68 (s, 3H, OCH₃), 4.39 (m, 1H, CH₂), 4.51 (m, 2H, CH), 4.73 (m, 1H, CH₂), 4.90 (m, 1H, CH), 5.66 (s, 1H, CH), 6.72 (d, $J=8$ Hz, 1H, NH), 7.06-7.21 (m, H, ArH), 7.57 (d, $J=9.2$ Hz, 1H, NH), 8.35 (m, 1H, CH). ¹³C NMR (CDCl₃, 75 MHz) δ 11.1 (CH₃), 15.5 (CH₃), 24.5 (CH₃), 24.8 (CH₂), 33.1 (CH₃), 37.2 (CH), 38.0 (CH₂), 48.3 (CH₂), 52.4 (OCH₃), 53.1 (CH), 57.4 (CH), 58.2 (C), 63.7 (C), 67.7 (CH), 78.4 (CH), 126.2 (CH), 127.0 (C), 128.5 (CH), 129.2 (CH), 135.6 (CH), 143.2 (C), 159.6 (CO), 165.5 (CO), 170.3 (CO), 171.9 (CO). IR: (film) 1795 cm⁻¹ (β-lactam), 1745 cm⁻¹ (CO ester), 1643 cm⁻¹ (CO amide). HRMS-ESI (*m/z*): calcd for C₂₇H₃₄Br₂KN₆O₅S [M+K]⁺: 751.03097; found: 751.02874.

1.10. (2S)-Methyl 2-((2S)-2-(1-((2S)-6,6-dibromo-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptan-2-yl)methyl)-1H-1,2,3-triazole-4-carboxamido)-3-methylbutanamido)-3-phenylpropanoate (7i).

¹H NMR (CDCl₃, 300 MHz) δ 0.94 (t, $J=7.2$ Hz, 6H, CH₃), 1.55 (s, 3H, CH₃), 1.59 (s, 3H, CH₃), 2.19 (m, 1H, CH), 3.05 (dd, $J_1=14$ Hz, $J_2=6.5$ Hz, 1H, CH₂), 3.12 (dd, $J_1=14$ Hz, $J_2=6$ Hz, 1H, CH₂), 3.68 (s, 3H, OCH₃), 4.37 (dd, $J_1=13.4$ Hz, $J_2=10.3$ Hz, 1H, CH₂), 4.52 (m, 1H, CH), 4.53 (m, 1H, CH), 4.71 (dd, $J_1=13.4$ Hz, $J_2=4.2$ Hz, 1H, CH₂), 4.91 (m, 1H, CH), 5.66 (s, 1H, CH), 6.79 (d, $J=8$ Hz, 1H, NH), 7.07-7.18 (m, 5H, ArH), 7.60 (d, $J=9$ Hz, 1H, NH), 8.36 (s, 1H, CH). ¹³C NMR (CDCl₃, 75 MHz) δ 18.0 (CH₃), 19.2 (CH₃), 24.4 (CH₃), 31.1 (CH), 33.2 (CH₃), 38.0 (CH₂), 48.4 (CH₂), 52.3 (OCH₃), 53.1 (CH), 58.1 (CH), 58.6 (C), 63.7 (C), 67.7 (CH), 78.4 (CH), 126.3 (CH), 127.1 (CH), 128.5 (CH), 129.2 (CH), 135.6 (C), 143.2 (C), 159.7 (CO), 165.6 (CO), 170.3 (CO), 171.8 (CO). IR: (film) 1789 cm⁻¹ (β-lactam), 1737 cm⁻¹ (CO ester), 1645 cm⁻¹ (CO amide). HRMS-ESI (*m/z*): calcd for C₂₆H₃₂Br₂N₆NaO₅S [M+Na]⁺: 721.04139; found: 721.04279.

1.11. (2S)-Methyl 2-((2S)-1-(1-(((2S)-6,6-dibromo-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptan-2-yl)methyl)-1H-1,2,3-triazole-4-carboxamido)pyrrolidine-2-carboxamido)-3-phenylpropanoate (**7j**).

⁵ **¹H NMR** (CDCl₃, 300 MHz) δ 1.58 (s, 3H, CH₃), 1.60 (s, 3H, CH₃), 1.9 (m, 2H, CH₂), 2.32 (m, 2H, CH₂), 2.91-3.20 (m, 2H, CH₂), 3.70 (s, 3H, OCH₃), 3.73 (m, 2H, CH₂), 4.07 (m, 2H, CH₂), 4.40 (m, 1H, CH), 4.44 (m, 1H, CH₂), 4.67 (m, 1H, CH₂), 4.76 (m, 1H, CH), 4.85 (m, 1H, CH), 5.64 (s, 1H, CH), 6.90 (m, 1H, NH), 7.06-7.22 (m, 5H, ArH), 7.45 (t, J=8 Hz, 1H, NH), 8.25 (s, 1H, CH). **¹³C NMR** (CDCl₃, 75 MHz) δ 24.2 (CH₃), 24.4 (CH₂), 25.1 (CH₂), 25.5 (CH₂), 33.2 (CH₃), 37.9 (CH₂), 48.1 (CH₂), 49.3 (CH₂), 52.2 (OCH₃), 53.1 (CH), 58.5 (C), 60.8 (CH), 63.6 (C), 67.9 (CH), 78.4 (CH), 114.4 (C), 126.8 (CH), 128.2 (CH), 128.4 (CH), 128.7 (CH), 129.1 (CH), 135.9 (C), 144.5 (C), 149.9 (C), 165.5 (CO), 168.4 (CO), 170.5 (CO), 171.9 (CO). **IR:** (film) 1789 cm⁻¹(β-lactam), 1745 cm⁻¹ (CO ester), 1681 cm⁻¹ (CO amide). **HRMS-ESI** (m/z): calcd for C₂₆H₃₀Br₂KN₆O₅S [M+K]⁺: 734.99967; found: 734.99935.

²⁰ **1.12.** (2S)-Methyl 2-((2S)-2-(1-(((2S)-6,6-dibromo-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptan-2-yl)methyl)-1H-1,2,3-triazole-4-carboxamido)-4-methylpentanamido)-4-methylpentanoate (**7k**).

²⁵ **¹H NMR** (CDCl₃, 300 MHz) δ 0.82-0.97 (m, 12 H, CH₃), 1.55 (s, 3H, CH₃), 1.58 (s, 3H, CH₃), 1.50-1.80 (m, 4H, CH₂), 1.63-1.81 (m, 2H, 2CH), 3.72 (s, 3H, OCH₃), 4.35 (dd, J₁=13.7 Hz, J₂=10 Hz, 1H, CH₂), 4.49 (dd, J₁=10 Hz, J₂=3.9 Hz, 1H, CH), 4.60 (m, 1H, CH), 4.68-4.72 (m, 2H, CH and CH₂), 5.65 (s, 1H, CH), 6.80 (d, J=8 Hz, 1H, NH), 7.49 (d, J=8.4 Hz, 1H, NH), 8.32 (m, 1H, CH). **¹³C NMR** (CDCl₃, 75 MHz) δ 21.9 (CH₃), 22.0 (CH₃), 22.6 (CH₃), 22.8 (CH₃), 24.5 (CH₃), 24.7 (CH), 24.8 (CH), 33.2 (CH₃), 41.1 (CH₂), 41.4 (CH₂), 48.4 (CH₂), 50.7 (CH), 51.3 (CH), 52.4 (OCH₃), 58.5 (C), 63.7 (C), 67.8 (CH), 78.4 (CH), 126.2 (CH), 143.1 (C), 159.7 (CO), 165.6 (CO), 171.3 (CO), 173.3 (CO). **IR:** (film) 1789 cm⁻¹(β-lactam), 1745 cm⁻¹ (CO ester), 1651 cm⁻¹ (CO amide). **HRMS-ESI** (m/z): calcd for C₂₄H₃₇Br₂N₆O₅S [M+H]⁺: 679.09074; found: 679.08736.

⁴⁰ **1.13.** (2S)-Methyl 2-((2S,3S)-2-(1-(((2S)-6,6-dibromo-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptan-2-yl)methyl)-1H-1,2,3-triazole-4-carboxamido)-3-methylpentanamido)-3-(4-hydroxyphenyl)propanoate (**7l**).

¹H NMR (CDCl₃, 300 MHz) δ 0.92 (d, J=6.2 Hz 3H, CH₃), 0.93 (d, J=6.2, 3H, CH₃), 1.59 (s, 3H, CH₃), 1.59-1.76 (m, 2H, CH₂), 1.61 (s, 3H, CH₃), 2.91-3.16 (m, 2H, CH₂), 3.76 (s, 3H, CH₃), 4.33 (m, 1H, CH₂), 4.51 (m, 1H, CH), 4.62 (m, 1H, CH), 4.80 (m, 1H, CH), 5.71 (s, 1H, CH), 6.44-6.85 (m, ArH), 6.76 (d, J=8 Hz, 1H, NH), 7.37 (d, J=8.4 Hz, 1H, NH), 8.22 (s, 1H, CH). **¹³C NMR** (CDCl₃, 75 MHz) δ 21.9 (CH₃), 22.9 (CH₃), 24.7 (CH₃), 33.2 (CH₃), 36.5 (CH₂), 39.9 (CH₂), 48.4 (CH₂), 51.1 (CH), 52.5 (CH), 53.0 (CH) 58.0 (C), 63.6 (C), 68.2 (CH), 78.5 (CH), 115.3 (CH), 126.9 (CH), 130.3 (CH), 142.8 (C), 155.0 (C), 159.8 (CO), 166.7 (CO), 170.8 (CO), 171.9 (CO). **IR:** (film) 1789 cm⁻¹(β-lactam), 1745 cm⁻¹ (CO ester), 1645 cm⁻¹ (CO amide). **HRMS-ESI** (m/z): calcd for C₂₇H₃₅Br₂N₆O₆S [M+H]⁺: 729.0700; found: 729.06992.

1.14. (2S)-Methyl 2-((2S)-2-(1-(((2S,6S)-6-bromo-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptan-2-yl)methyl)-1H-1,2,3-triazole-4-carboxamido)-4-(methylthio)butanamido)-3-phenylpropanoate (**7m**).

¹H NMR (CDCl₃, 300 MHz) δ 1.58 (s, 3H, CH₃), 1.61 (s, 3H, CH₃), 2.06 (s, 3H, CH₃), 2.00-2.23 (m, 2H, CH₂), 2.58 (t, J=7 Hz, 2H, CH₂), 3.07 (dd, J₁=13.8 Hz, J₂=6.2 Hz, 1H, CH₂), 3.16 (dd, J₁=14 Hz, J₂=6.2 Hz, 1H, CH₂) 3.69 (s, 3H, OCH₃), 4.37 (dd, J₁=14 Hz, J₂=5.4 Hz, 1H, CH₂), 3.71 (s, 3H, OCH₃), 4.33-4.49 (m, 2H, CH and CH₂), 4.76-4.83 (m, 1H, CH), 4.85-4.92 (m, 1H, CH), 5.65 (s, 1H, CH), 6.78 (d, J=8 Hz, 1H, NH), 7.07-7.22 (m, 5H, ArH), 7.67 (d, J=8 Hz, 1H, NH), 8.19 (s, 1H, CH). **¹³C NMR** (CDCl₃, 75 MHz) δ 15.0 (CH₃), 24.5 (CH₃), 30.0 (CH₂), 31.1 (CH₂), 33.2 (CH₃), 37.8 (CH₂), 48.4 (CH₂), 51.6 (CH), 52.4 (OCH₃), 53.2 (CH), 58.5 (C), 63.6 (C), 67.9 (CH), 78.5 (CH), 126.0 (CH), 127.2 (CH), 128.6 (CH), 129.2 (CH), 135.5 (C), 143.1 (C), 159.6 (CO), 165.6 (CO), 170.1 (CO), 171.6 (CO). **IR:** (film) 1789 cm⁻¹(β-lactam), 1745 cm⁻¹ (CO ester), 1681 cm⁻¹ (CO amide). **HRMS-ESI** (m/z): calcd for C₂₆H₃₂Br₂N₆NaO₅S [M+Na]⁺: 753.0140; found: 753.01346.

⁸⁰ **1.15.** (2S)-Methyl 2-(1-(((2S)-6,6-dibromo-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptan-2-yl)methyl)-1H-1,2,3-triazole-4-carboxamido)-4-methylpentanamido (**7n**).

¹H NMR (CDCl₃, 300 MHz) δ 0.96 (s, 3H, CH₃), 0.98 (s, 3H, CH₃), 1.57 (s, 3H, CH₃), 1.59 (s, 3H, CH₃), 1.67-1.80 (m, 3H, CH and CH₂), 3.76 (s, 3H, OCH₃), 4.33-4.46 (m, 2H, CH and CH₂), 4.64-4.71 (m, 1H, CH₂), 4.78-4.86 (m, 1H, CH), 5.7 (s, 1H, CH), 7.46 (d, J=8.6 Hz, 1H, NH), 8.35 (s, 1H, CH). **¹³C NMR** (CDCl₃, 75 MHz) δ 21.8 (CH₃), 22.8 (CH₃), 24.5 (CH), 24.8 (CH₃), 33.3 (CH₃), 41.5 (CH₂), 48.2 (CH₂), 50.5 (CH), 52.4 (OCH₃), 58.6(C), 63.5 (C), 67.9 (CH), 78.4 (CH), 126.4 (CH), 143.1 (C), 159.6 (CO), 165.6 (CO), 172.7 (CO). **IR:** (film) 1791 cm⁻¹(β-lactam), 1735 cm⁻¹ (CO ester), 1649 cm⁻¹ (CO amide). **HRMS-ESI** (m/z): calcd for C₁₈H₂₆Br₂N₅O₄S [M+H]⁺: 566.0072; found: 566.00711.

⁹⁵ **1.16.** (2S)-Methyl 2-(1-(((2S)-6,6-dibromo-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptan-2-yl)methyl)-1H-1,2,3-triazole-4-carboxamido)-3-(4-hydroxyphenyl)propanoate (**7o**).

¹⁰⁰ **¹H NMR** (CDCl₃, 300 MHz) δ 1.56 (s, 3H, CH₃), 1.58 (s, 3H, CH₃), 3.12 (m, 2H, CH₂), 3.75 (s, 3H, OCH₃), 4.36 (m, 1H, CH₂), 4.38 (m, 1H), 4.65 (q, J=11 Hz, 1H, CH₂), 5.01 (m, 1H, CH), 5.62 (s, 1H, CH), 6.69-7.04 (m, 4H, ArH), 7.53 (d, J=8.6 Hz, 1H, NH), 8.09 (s, 1H, CH). **¹³C NMR** (CDCl₃, 75 MHz) δ 24.5 (CH₃), 33.2 (CH₃), 37.6 (CH₂), 48.3 (CH₂), 52.4 (CH₃), 53.3 (CH), 58.4 (C), 63.6 (C), 67.9 (CH), 78.4 (CH), 115.5 (CH), 126.1 (CH), 127.4 (C), 130.4 (CH), 143.0 (C), 155.0 (C), 159.34 (CO), 165.5 (CO), 171.3 (CO). **IR:** (film) 1795 cm⁻¹(β-lactam), 1745 cm⁻¹ (CO ester), 1655 cm⁻¹ (CO amide). **HRMS-ESI** (m/z): calcd for C₂₁H₂₃Br₂N₅NaO₅S [M+Na]⁺: 637.9684; found: 637.9678.

¹¹⁵ **1.17.** (2S)-Methyl 2-((2S)-2-(1-(((2S)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptan-2-yl)methyl)-1H-1,2,3-triazole-4-carboxamido)-4-methylpentanamido)-3-phenylpropanoate (**7p**).

¹H NMR (CDCl₃, 300 MHz) δ 0.91 (d, *J*= 5.7 Hz, 3H, CH₃), 0.92 (d, *J*= 5.7 Hz, 3H, CH₃), 1.59 (s, 6H, 2 CH₃), 1.65-1.77 (m, 3H, CH and CH₂), 3.01-3.18 (m, 2H, CH₂), 3.06-3.13 (m, 1H, CH₂), 3.53 (dd, *J*₁= 16 Hz, *J*₂= 4.3 Hz, 1H, CH₂), 3.69 (s, 3H, OCH₃), 4.31-4.33 (m, 2H, CH and CH₂), 4.57-4.69 (m, 2H, CH and CH₂), 4.82-4.89 (m, 1H, CH), 5.16 (dd, *J*₁= 4 Hz, *J*₂= 2 Hz, 1H, CH), 6.73 (d, *J*= 7.6 Hz, 1H, NH), 7.05-7.11 (m, 5H, ArH), 7.35 (d, *J*= 8.3 Hz, 1H, NH), 8.19 (s, 1H, CH). **¹³C NMR (CDCl₃, 75 MHz)** δ 21.8 (CH₃), 22.9 (CH₃), 24.6 (CH), 24.9 (CH₃), 33.0 (CH₃), 37.9 (CH₂), 40.5 (CH₂), 48.1 (CH₂), 49.07 (CH), 51.3 (CH), 52.3 (OCH₃), 53.2 (CH), 58.9 (CH), 63.7 (C), 68.1 (CH), 126.2 (CH), 127.0 (CH), 128.4 (CH), 129.2 (CH), 135.7 (C), 142.8 (C), 159.9 (CO), 171.0 (CO), 171.7 (CO), 173.2 (CO). **IR:** (film) 1776 cm⁻¹ (β-lactam), 1745 cm⁻¹ (CO ester), 1658 cm⁻¹ (CO amide). **HRMS-ESI (m/z):** calcd for C₂₇H₃₇N₆O₅S [M+H]⁺: 557,2546; found: 557.25376.

1.18. (2S)-Methyl 2-((2S)-2-(1-(((2S)-6,6-dibromo-3,3-dimethyl-4,4-dioxido-7-oxo-4-thia-1-azabicyclo[3.2.0]heptan-2-yl)methyl)-1*H*-1,2,3-triazole-4-carboxamido)-4-methylpentanamido)-3-phenylpropanoate (7q).

¹H NMR (CDCl₃, 300 MHz) δ 0.88 (d, *J*= 6 Hz, 3H, CH₃), 0.90 (d, *J*= 6 Hz, 3H, CH₃), 1.44 (s, 3H, CH₃), 1.58 (s, 3H, CH₃), 1.61-1.76 (m, 3H, CH and CH₂), 3.01-3.18 (m, 2H, CH₂), 3.05 (dd, *J*₁= 13.8 Hz, *J*₂= 6.3 Hz, 1H, CH₂), 3.13 (dd, *J*₁= 13.8 Hz, *J*₂= 5.9 Hz, 1H, CH₂), 3.68 (s, 3H, OCH₃), 3.52 (m, 1H, CH), 3.60-3.70 (m, 2H, CH₂), 4.70-4.78 (m, 1H, CH), 4.88 (m, 1H, CH), 5.16 (s, 1H, CH), 7.02 (d, *J*= 8.2 Hz, 1H, NH), 7.05-7.15 (m, 5H), 7.53 (d, *J*= 8.6 Hz, 1H, NH), 8.17 (s, 1H, CH). **¹³C NMR (CDCl₃, 75 MHz)** δ 18.2 (CH₃), 19.8 (CH₃), 22.0 (CH₃), 22.8 (CH₃), 24.7 (CH), 37.9 (CH₂), 41.1 (CH₂), 44.8 (C), 49.1 (CH₂), 51.4 (CH), 52.4 (OCH₃), 53.3 (CH), 62.1 (CH), 64.5 (C), 74.0 (CH), 127.0 (CH), 127.3 (CH), 128.4 (CH), 129.2 (CH), 135.7 (C), 143.1 (C), 159.8 (CO), 165.2 (CO), 171.2 (CO), 171.9 (CO). **IR:** (film) 1807 cm⁻¹ (β-lactam), 1745 cm⁻¹ (CO ester), 1643 cm⁻¹ (CO amide), 1336 and 1128 (sulfone). **HRMS-ESI (m/z):** calcd for C₂₇H₃₄Br₂N₆NaO₇S [M+Na]⁺: 767,0474; 7 found: 67.04602.

2. Anticancer screening

2.1 Cell lines and culture conditions

HeLa (ATCC CCL-2) cells were grown in minimum essential medium (MEM) supplemented with 10% fetal bovine serum (FBS), 2 mM L-glutamine, 50 U/mL penicillin and 50 µg/mL streptomycin. B16-F0 cell line, kindly provided by the Laboratory of Molecular Oncology (Quilmes National University, Buenos Aires, Argentina), was grown in RPMI-1640 supplemented as indicated above. NMuMG (ATCC CRL-1636) cells, gently provided by the Institute of Oncology Angel H. Roffo (Buenos Aires, Argentina), were cultured in DMEM-F12 containing 10% FBS, 2 mM L-glutamine, 0.6% Hepes, 50 U/mL penicillin and 50 µg/mL streptomycin.

2.2 Cell proliferation assay

Cells were placed in 96-well microplates at a density of 2 x 10⁴ cells/well (HeLa and NMuMG) or 1 x 10⁴ cells/well (B16-F0) and incubated for 72 h at 37 °C in the presence or absence of 20 µM of the different compounds in a total volume of 0.2 ml of culture medium. Compounds were dissolved in dimethylsulfoxide (DMSO) as 10 mM stock solutions and stored at -70 °C. Prior to

use, the compounds were diluted 1:10 in ethanol and added at the indicated concentrations to the culture medium. Control cells were treated under similar conditions and a final concentration of 20 µL vehicle/mL of culture medium was used in all experiments. Total cell number was evaluated by colorimetric determination of hexosaminidase levels, a ubiquitous lysosomal enzyme.¹ Briefly, cells were washed twice with phosphate-buffered saline and then incubated at 37 °C with 60 µL of 3.25 mM *p*-nitrophenol-*N*-acetyl-β-D-glucosaminide dissolved in 50 mM citrate buffer, pH 5, 0.25% Triton X-100. After 45-120 min, the color reaction was developed and the enzyme activity was blocked by adding 90 µL of 50 mM glycine buffer, pH 10.4, containing 5 mM EDTA. Absorbance values were measured at 405 nm in a visible plate reader (Biotrak II, Amersham Biosciences, USA). The molar drug concentrations required to cause 50% growth inhibition (IC₅₀) were determined from dose-response curves.

75 .

Notes and references

- 1 a) U. Landegren, *J. Immunol. Methods*, 1984, **67**, 379-388. b) M. Cárdenas, M. Marder, V.C. Blank, L.P. Roguin, *Bioorg. Med. Chem.*, 2006, **14**, 2966-2971.